Summary
This filing is an amendment to a previous 8-K report filed by Regeneron Pharmaceuticals, Inc. (REGN) on November 22, 2011. The amendment clarifies information regarding board committee appointments for Dr. Marc Tessier-Lavigne, who was elected as a director on November 18, 2011. The original report stated that committee assignments were not yet determined at the time of filing. Investors should note that the sole purpose of this amendment is to disclose that, as of January 20, 2012, Dr. Tessier-Lavigne was appointed to both the Compensation Committee and the Technology Committee of Regeneron's Board of Directors. This information is a follow-up to the initial director election and provides completeness to the board composition and committee structure.
Key Highlights
- 1Amendment to a previous 8-K filing from November 22, 2011.
- 2Clarifies board committee appointments for newly elected director, Dr. Marc Tessier-Lavigne.
- 3Dr. Tessier-Lavigne was elected to the Board of Directors on November 18, 2011.
- 4The amendment was filed to disclose previously undetermined committee assignments.
- 5As of January 20, 2012, Dr. Tessier-Lavigne was appointed to the Compensation Committee.
- 6As of January 20, 2012, Dr. Tessier-Lavigne was also appointed to the Technology Committee.